Page 65 - Human Use News Today

The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion regarding sacituzumab govitecan-hziy monotherapy in select patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion of Adtralza for injection in a new single-dose 2 ml pre-filled pen, according to a press release. Adtralza (tralokinumab, LEO Pharma), a high-affinity fully human monoclonal antibody, has previously been approved for a single dose injection of 150 mg from a 1 ml pre-filled syringe

Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine •The application reflects guidance from EMA and other major health authorities to pr...

The European Medicines Agency has validated the marketing authorization application for coacillium for the treatment of moderate and severe alopecia areata in children and adolescents, Legacy Healthcare announced in a press release. The application is now under the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) review.

/PRNewswire/ -- Legacy Healthcare (or the "Company"), today announced that its Marketing Authorisation Application (MAA) to the European Medicines Agencys...

Well, it failed to achieve what i had hoped it would achieve and what i believe ethically it needs to achieve, thats true. it didnt totally fail because there is now an animal rights movement which is a powerfulforce in many of the countries in the world and many people kindly credit my book as having triggered or inspired that movement. and that movement has had some achievements in some countries, i wouldnt deny that, but if we look at it globally, there are more animals in factory farms than ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 15, 2023--

- Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate, and a median duration of response of 1.5 years (18.4 months) - - Given over

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 15, 2023--

/PRNewswire/ -- Life Molecular Imaging (LMI) is pleased to announce the publication of a significant retrospective analysis utilizing the amyloid positron...